LUND, Sweden, April 22, 2021 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January – March, 2021. Highlights for the first quarter 2021 First commercial sales of...